Charles River Laboratories International, Inc. Share Price
Equities
CRL
US1598641074
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 219.70 USD | -1.69% |
|
+0.40% | +10.14% |
| Capitalization | 10.81B 9.29B 8.62B 8.05B 14.99B 983B 16.11B 99.56B 39.21B 468B 40.55B 39.72B 1,710B | P/E ratio 2025 * |
52.4x | P/E ratio 2026 * | 30.3x |
|---|---|---|---|---|---|
| Enterprise value | 12.74B 10.95B 10.16B 9.49B 17.67B 1,158B 18.98B 117B 46.22B 551B 47.79B 46.81B 2,015B | EV / Sales 2025 * |
3.18x | EV / Sales 2026 * | 3.03x |
| Free-Float |
97.96% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Charles River Laboratories International, Inc.
| 1 day | -1.69% | ||
| 1 week | +0.40% | ||
| Current month | +10.14% | ||
| 1 month | +11.49% | ||
| 3 months | +23.07% | ||
| 6 months | +42.22% | ||
| Current year | +10.14% |
| 1 week | 214.11 | 227.5 | |
| 1 month | 194.93 | 228.88 | |
| Current year | 194.93 | 228.88 | |
| 1 year | 91.86 | 228.88 | |
| 3 years | 91.86 | 275 | |
| 5 years | 91.86 | 460.21 | |
| 10 years | 65.7 | 460.21 |
| Manager | Title | Age | Since |
|---|---|---|---|
James Foster
CEO | Chief Executive Officer | 75 | 31/12/1991 |
Michael Knell
DFI | Director of Finance/CFO | 49 | 28/09/2025 |
Namandje Bumpus
CTO | Chief Tech/Sci/R&D Officer | 45 | 11/01/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
James Foster
CHM | Chairman | 75 | 31/12/1999 |
Martin MacKay
BRD | Director/Board Member | 69 | 04/07/2017 |
Virginia Wilson
BRD | Director/Board Member | 70 | 30/09/2019 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.69% | +0.40% | +34.37% | -5.92% | 10.81B | ||
| -2.36% | -3.50% | -3.05% | +11.52% | 48.93B | ||
| -1.49% | -1.32% | +20.43% | +6.92% | 40.48B | ||
| -0.03% | +1.26% | +60.98% | +23.20% | 37.42B | ||
| -0.71% | -3.69% | +20.76% | +39.16% | 31.03B | ||
| -2.43% | +2.65% | +198.54% | +335.64% | 23.25B | ||
| -1.16% | +1.95% | +81.09% | +166.96% | 17.21B | ||
| Average | -1.41% | +0.04% | +59.02% | +82.50% | 29.88B | |
| Weighted average by Cap. | -1.40% | -0.13% | +47.75% | +64.75% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 4.01B 3.44B 3.19B 2.98B 5.55B 364B 5.97B 36.89B 14.53B 173B 15.02B 14.72B 633B | 4.08B 3.5B 3.25B 3.03B 5.65B 370B 6.07B 37.53B 14.78B 176B 15.29B 14.97B 644B |
| Net income | 215M 185M 171M 160M 298M 19.53B 320M 1.98B 780M 9.3B 806M 790M 33.99B | 381M 327M 304M 284M 528M 34.62B 567M 3.51B 1.38B 16.48B 1.43B 1.4B 60.23B |
| Net Debt | 1.93B 1.66B 1.54B 1.44B 2.68B 176B 2.88B 17.79B 7.01B 83.58B 7.24B 7.1B 305B | 1.54B 1.32B 1.23B 1.15B 2.14B 140B 2.3B 14.19B 5.59B 66.67B 5.78B 5.66B 244B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/01/26 | 219.70 $ | -1.69% | 866,972 |
| 15/01/26 | 223.47 $ | +3.27% | 779,526 |
| 14/01/26 | 216.39 $ | -1.19% | 936,397 |
| 13/01/26 | 218.99 $ | +0.08% | 1,054,449 |
Delayed Quote Nyse, January 16, 2026 at 09:00 pm
More quotesTrader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.

Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- CRL Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















